<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00030992</url>
  </required_header>
  <id_info>
    <org_study_id>020130</org_study_id>
    <secondary_id>02-C-0130</secondary_id>
    <nct_id>NCT00030992</nct_id>
    <nct_alias>NCT00033670</nct_alias>
  </id_info>
  <brief_title>BMS 247550 to Treat Kidney Cancer</brief_title>
  <official_title>A Phase II Clinical Trial of BMS-247550 (NSC 710428), an Epothilone B Analog, in Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine whether the experimental drug BMS 247550 (Ixabepilone) is an
      effective treatment for kidney cancer. BMS 247550 belongs to a class of drugs called
      epothilones that interfere with the ability of cancer cells to divide. In the way they kill
      cells, they are very similar to a class of compounds known as the taxanes, which include the
      drug Taxol. Other characteristics of the epothilones, however, enable them to work in cells
      that are resistant to Taxol.

      Patients 18 years of age or older with kidney cancer that has not spread to the central
      nervous system (unless the brain tumor has remained stable for at least six months after
      surgical or radiation treatment) may be eligible for this study. Pregnant or nursing women
      may not participate. Candidates are screened with various tests that may include blood and
      urine tests, electrocardiogram (EKG), and chest x-ray. Computerized tomography (CT) scans or
      X-rays, and possibly nuclear medicine studies may be done to determine the extent of disease.

      Participants receive BMS 247550 by a 1-hour infusion into a vein for 5 consecutive days (days
      1, 2, 3, 4 and 5) of each 21-day treatment cycle. Patients must stay in the National
      Institutes of Health (NIH) area near Bethesda, Maryland, for 7 to 8 days during the first
      treatment cycle and for the 5 days of treatment in subsequent cycles. The total number of
      cycles will vary among patients, depending on their individual clinical situation. The drug
      dose may be increased gradually in subsequent cycles in patients who can tolerate such
      increases. In addition, participants undergo the following tests and procedures:

        -  Periodic physical examinations and frequent blood tests

        -  X-ray and other imaging studies to determine if the tumor is responding to the
           treatment.

        -  Tumor biopsies to confirm the diagnosis or spread of tumor and to examine the reaction
           of certain proteins in cancer cells to BMS 247550. Two biopsies will be done. For this
           procedure, a small piece of tumor tissue is withdrawn through a needle under local
           anesthetic.

      Treatment will be stopped in patients whose tumor grows while receiving BMS 247550. Patients
      whose tumor disappears completely will be followed at NIH periodically for examinations and
      tests. Patients whose disease does not completely resolve or whose disease recurs may be
      advised of other appropriate research protocols at NIH or, if none are available, will be
      returned to the care of their local doctor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

      BMS-247550 (NSC 710428), (ixabepilone) is a semi-synthetic analog of the natural product
      epothilone B.

      The epothilones are a novel class of non-taxane microtubule-stabilizing agents obtained from
      the fermentation of the cellulose degrading myxobacteria, Sorangium cellulosum.

      BMS-247550 is active against cancer models that are naturally insensitive to paclitaxel or
      have developed resistance to paclitaxel, both in-vitro and in-vivo.

      Objectives

      Establish the efficacy of the investigational agent BMS-247550 in patients with renal cell
      carcinoma when administered as a one hour infusion on day 1 to 5 every 21 days.

      Evaluate the plasma pharmacokinetics of BMS-247550.

      Explore the pharmacodynamics of BMS-247550 using an assay that measures the amount of
      endogenous tubulin in peripheral blood mononuclear cells (PBMC) that exists in the
      polymerized versus the unpolymerized state.

      Determine the extent to which pharmacodynamic changes are observed over a range of doses of
      BMS-247550.

      Determine if cross-resistance to BMS-247550 exists in patients who have previously received
      sorafenib or sunitinib.

      Eligibility:

      Age greater than 18.

      Pathological confirmation of renal cell carcinoma.

      Prior chemotherapy including sorafenib and sunitinib is allowed.

      Design:

      Phase II study.

      BMS-247550 will be administered on days 1 through 5, every 21 days.

      Restaging will be done every two cycles.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>Response rate is the percentage of participants with a response assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) is disappearance of all target lesions, Partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions,progressive disease (PD) is at least a 20% increase in the sum of the LD of target lesions or the appearance of one or more new lesions, stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>10 years</time_frame>
    <description>Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>BMS-247550</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One hour infusion on five successive days (daily x 5) every three weeks. Starting dose of 6 mg/m^2/day for a total per cycle dose of 30 mg/m^2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-247550</intervention_name>
    <description>One hour infusion on five successive days (daily x 5) every three weeks. Starting dose of 6 mg/m^2/day for a total per cycle dose of 30 mg/m^2</description>
    <arm_group_label>BMS-247550</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranitidine</intervention_name>
    <description>50 mg 30-60 minutes prior to Ixabepilone (BMS-247550)</description>
    <arm_group_label>BMS-247550</arm_group_label>
    <other_name>Zantac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine</intervention_name>
    <description>50 mg intravenously 30-60 minutes prior to Ixabepilone (BMS-247550)</description>
    <arm_group_label>BMS-247550</arm_group_label>
    <other_name>Benadryl</other_name>
    <other_name>Diphenhist</other_name>
    <other_name>Diphedryl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Patients must fulfill all of the following criteria to be eligible for study admission:

          1. Age greater than or equal to 18 years.

          2. Histologic or cytologic confirmation of renal cell carcinoma (clear cell, type I and
             type II papillary, chromophobe, collecting duct and medullary).

             Patients should either:

               1. have received interleukin-2 (IL-2);

               2. have been evaluated for therapy with IL-2 and deemed to be ineligible; or (c)
                  have been evaluated for therapy with IL-2 and refused treatment.

          3. Measurable extent of disease.

          4. Performance Status Eastern Cooperative Oncology Group (ECOG) 0-2.

          5. Life expectancy of 3 months or greater.

          6. Suitable candidate for receiving planned therapy as evidenced by screening laboratory
             assessments of hematologic, renal, hepatic, and metabolic functions:

             platelet count greater than or equal to 100,000/mL, absolute granulocyte count (AGC)
             greater than or equal to 1,500/mL, serum creatinine less than or equal to 1.6 or a
             measured creatinine clearance greater than or equal to 40 ml/min, serum glutamic
             pyruvic transaminase (SGPT) and serum glutamic oxaloacetic transaminase (SGOT) less
             than or equal to 2.5 x normal limit (NL), and total bilirubin less than or equal to
             1.5 x NL (in patients with clinical evidence of Gilberts' disease, less than or equal
             to 3 x NL).

          7. Greater than or equal to 4 weeks from prior cytotoxic chemotherapy, radiation or
             immunotherapy; greater than or equal to 2 weeks from prior targeted-therapy
             (cytostatic agents); such patients should have recovered from toxicity from the prior
             therapy.

          8. No serious intercurrent medical illness.

          9. The ability to understand and willingness to sign a written informed consent form, and
             to comply with the protocol.

         10. Patients should either: (a) have received sorafenib and or sunitinib and had
             progressive disease while receiving the drug(s) or (b) been intolerant to the
             drugs(s), or (c) been evaluated for therapy with sorafenib and or sunitinib and deemed
             to be ineligible; or (d) have been evaluated for therapy with sorafenib and or
             sunitinib and refused treatment.

        EXCLUSION CRITERIA:

        Patients with any of the following will be excluded from study entry:

          1. Pregnant or nursing women are not eligible; neither are women or men of childbearing
             potential unless using effective contraception as determined by the patient's
             physician.

          2. Patients with a history of central nervous system (CNS) metastases, because
             symptoms/signs of progressive disease may be confused with drug-related toxicities,
             unless control has been achieved with either radiation or surgical resection at least
             six months prior to enrollment on study.

          3. Patients who are poor medical risk because of other non-malignant systemic disease or
             active, uncontrolled infection.

          4. Human immunodeficiency virus (HIV) seropositive patients. Patients infected with the
             HIV virus will be excluded from this trial because the effect of BMS-247550 on HIV
             replication and/or the immune system is unknown and may be potentially harmful.

          5. Prior craniospinal radiation, or total body irradiation (TBI).

          6. Patients receiving other investigational drugs, or St. John's Wort (St. John's Wort
             can induce P450 and alter drug metabolism).

          7. Common Toxicity Criteria (CTC) Grade 2 or greater motor or sensory neuropathy.

          8. Known prior severe hypersensitivity reactions to agents containing Cremophor EL.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tito Fojo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, National Institutes of Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2002-C-0130.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Wilson L, Jordan MA. Microtubule dynamics: taking aim at a moving target. Chem Biol. 1995 Sep;2(9):569-73. Review.</citation>
    <PMID>9383460</PMID>
  </reference>
  <reference>
    <citation>Huizing MT, Misser VH, Pieters RC, ten Bokkel Huinink WW, Veenhof CH, Vermorken JB, Pinedo HM, Beijnen JH. Taxanes: a new class of antitumor agents. Cancer Invest. 1995;13(4):381-404. Review.</citation>
    <PMID>7627725</PMID>
  </reference>
  <reference>
    <citation>Von Hoff DD. The taxoids: same roots, different drugs. Semin Oncol. 1997 Aug;24(4 Suppl 13):S13-3-S13-10. Review.</citation>
    <PMID>9335511</PMID>
  </reference>
  <results_reference>
    <citation>Huang H, Menefee M, Edgerly M, Zhuang S, Kotz H, Poruchynsky M, Huff LM, Bates S, Fojo T. A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2010 Mar 1;16(5):1634-41. doi: 10.1158/1078-0432.CCR-09-0379. Epub 2010 Feb 23.</citation>
    <PMID>20179242</PMID>
  </results_reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2002</study_first_submitted>
  <study_first_submitted_qc>February 20, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2002</study_first_posted>
  <results_first_submitted>June 6, 2012</results_first_submitted>
  <results_first_submitted_qc>June 6, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 20, 2012</results_first_posted>
  <last_update_submitted>August 13, 2012</last_update_submitted>
  <last_update_submitted_qc>August 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2012</last_update_posted>
  <responsible_party>
    <name_title>Antonio T. Fojo, M.D./National Cancer Institute</name_title>
    <organization>National Institutes of Health</organization>
  </responsible_party>
  <keyword>Epothilone B</keyword>
  <keyword>Ixabepilone</keyword>
  <keyword>Renal Cell Carcinoma</keyword>
  <keyword>Kidney Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Ranitidine</mesh_term>
    <mesh_term>Epothilones</mesh_term>
    <mesh_term>Epothilone B</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>102 participants were enrolled in this study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>BMS-247550</title>
          <description>One hour infusion on five successive days (daily x 5) every three weeks. Starting dose of 6 mg/m^2/day for a total per cycle dose of 30 mg/m^2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BMS-247550</title>
          <description>One hour infusion on five successive days (daily x 5) every three weeks. Starting dose of 6 mg/m^2/day for a total per cycle dose of 30 mg/m^2</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="102"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.21" spread="10.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate</title>
        <description>Response rate is the percentage of participants with a response assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) is disappearance of all target lesions, Partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions,progressive disease (PD) is at least a 20% increase in the sum of the LD of target lesions or the appearance of one or more new lesions, stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BMS-247550</title>
            <description>One hour infusion on five successive days (daily x 5) every three weeks. Starting dose of 6 mg/m^2/day for a total per cycle dose of 30 mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>Response rate is the percentage of participants with a response assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) is disappearance of all target lesions, Partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions,progressive disease (PD) is at least a 20% increase in the sum of the LD of target lesions or the appearance of one or more new lesions, stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.</description>
        <time_frame>10 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BMS-247550</title>
            <description>One hour infusion on five successive days (daily x 5) every three weeks. Starting dose of 6 mg/m^2/day for a total per cycle dose of 30 mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>BMS-247550</title>
          <description>One hour infusion on five successive days (daily x 5) every three weeks. Starting dose of 6 mg/m^2/day for a total per cycle dose of 30 mg/m^2</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCv2.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>(fever of unknown origin without clinically or microbiologically documented infection)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hemoglobin (hgb)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hemorrhage/bleeding associated with surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac left ventricular function</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Cardiac troponin T (cTnT)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Cardiac-ischemia/infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Circulatory or cardiac-Other (hypertension)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>CNS cerebrovascular ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pericardial effusion/pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Supraventricular arrhythmias (SVT/atrial fibrillation/flutter)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea (without colostomy)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Dysphagia, esophagitis, odynophagia (painful swallowing)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Melena/GI bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Fatigue (lethargy, malaise, asthenia)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>in the absence of neutropenia, where neutropenia is defined as AGC&lt; 1.0x109/L</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter-related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <description>(documented clinically or microbiologically) with grade 3 or 4 neutropenia</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Infection with neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Infection without neutropenia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Infection, Other (other than fever with neutropenia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Stomatitis/pharyngitis (oral/pharyngeal mucositis) for BMT</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>CPK (creatine phosphokinase)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hemoglobin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>SGOT (AST)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>SGPT (ALT)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint, muscle, or bone (osseous)-Other (fracture)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurologic-Other (autonomic neuropathy)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Neuropathic pain</sub_title>
                <description>e.g. jaw pain, neurologic pain, phantom limb pain, post-infectious neuralgia, or painful neuropathies</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Neuropathy-motor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pain-neuropathic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Seizure(s)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Vasovagal reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hematuria (in the absence of vaginal bleeding)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult respiratory distress syndrome (ARDS)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pulmonary-Other: malignant pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Voice changes/stridor/larynx</sub_title>
                <description>e.g. hoarseness, loss of voice, laryngitis</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCv2.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="52" subjects_affected="12" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Blood and lymphatic system disorders-Other, specify (bruising)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>fever of unknown origin without clinically or microbiologically documented infection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hemoglobin (hgb)</sub_title>
                <counts group_id="E1" events="235" subjects_affected="65" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hemorrhage/bleeding associated with surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hemorrhage/bleeding without grade 3 or 4 thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Transfusion:pRBCs</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac-ischemia/infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Circulatory or cardiac-Other (edema)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Palpitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear and labyrinth disorders-Other, specify (tinnitus)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>External auditory canal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Middle ear/hearing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Eye disorders-Other, specify (blepharitis)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Ocular-Other (blurred vision)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Tearing (watery eyes)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Vision-blurred vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Vision-flashing lights/floaters</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Abdominal pain or cramping</sub_title>
                <counts group_id="E1" events="19" subjects_affected="12" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="40" subjects_affected="30" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Diarrhea (without colostomy)</sub_title>
                <counts group_id="E1" events="95" subjects_affected="42" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Dyspepsia/heartburn</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>GI-Other (bloating)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="132" subjects_affected="48" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Salivary gland changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="66" subjects_affected="37" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="32" subjects_affected="13" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Chest pain (non-cardiac and non-pleuritic)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="19" subjects_affected="14" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Fatigue (lethargy, malaise, asthenia)</sub_title>
                <counts group_id="E1" events="220" subjects_affected="73" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Fever (in absence of neutropenia, where neutropenia is defined as AGC&lt;1.0x109/L)</sub_title>
                <counts group_id="E1" events="35" subjects_affected="30" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pain-Other (dysethesia)</sub_title>
                <counts group_id="E1" events="23" subjects_affected="17" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Rigors, chills</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip)</sub_title>
                <counts group_id="E1" events="19" subjects_affected="15" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter-related infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Infection without neutropenia</sub_title>
                <counts group_id="E1" events="41" subjects_affected="30" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Infection, Other (skin)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Infections and infestations-Other, specify (skin)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Stomatitis/pharyngitis (oral/pharyngeal mucositis)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Stomatitis/pharyngitis (oral/pharyngeal mucositis) for BMT</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising (in absence of grade 3 or 4 thrombocytopenia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Postoperative hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Wound-infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Wound-non-infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="12" subjects_affected="4" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Alkaline phosphokinase</sub_title>
                <counts group_id="E1" events="33" subjects_affected="24" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Alkaline phosphokinase increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Allergy-Other (rhinitis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Amylase</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="13" subjects_affected="6" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Cardiac troponin I increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Cholesterol high</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>CPK (creatine phosphokinase)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>CPK increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="14" subjects_affected="5" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hemoglobin increased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hypercholesterolemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="96" subjects_affected="34" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="30" subjects_affected="7" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Lymphocyte count increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="142" subjects_affected="46" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Partial thromboplastin time (PTT)</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="72" subjects_affected="27" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>SGOT (AST)</sub_title>
                <counts group_id="E1" events="48" subjects_affected="29" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>SGPT (ALT)</sub_title>
                <counts group_id="E1" events="31" subjects_affected="19" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="15" subjects_affected="5" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="88" subjects_affected="56" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="22" subjects_affected="16" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="12" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="28" subjects_affected="17" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="15" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="113" subjects_affected="62" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="12" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="9" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="45" subjects_affected="19" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="37" subjects_affected="18" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Arthralgia (joint pain)</sub_title>
                <counts group_id="E1" events="49" subjects_affected="31" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Joint, muscle, or bone (osseous)-Other (myalgia)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Muscle weakness (not due to neuropathy)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Myalgia (muscle ache)</sub_title>
                <counts group_id="E1" events="21" subjects_affected="14" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumor pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Tumor pain (onset or exacerbation of tumor pain due to treatment)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy-motor</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Dizziness/lightheadedness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Extrapyramidal/involuntary movement/restlessness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Leukoencephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Memory loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Nervous system disorders-Other, specify (vasovagal)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Neurologic-Other (dizziness)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Neuropathic pain</sub_title>
                <description>e.g. jaw pain, neurologic pain, phantom pain , post-infectious neuralgia, or painful neuropathies</description>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" events="88" subjects_affected="50" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Sense of smell</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Taste disturbance (dysgeusia)</sub_title>
                <counts group_id="E1" events="86" subjects_affected="40" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Mood alteration-anxiety agitation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Mood alteration-depression</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Mood alteration-euphoria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria (painful urination)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hematuria (in the absence of vaginal bleeding)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Renal/GU-Other (urgency)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Ureteral obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Urinary frequency/urgency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal bleeding</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Vaginal dryness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="39" subjects_affected="29" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pericardial effusion/pericarditis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Voice changes/stridor/larynx</sub_title>
                <description>e.g. hoarseness, loss of voice, laryngitis</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="76" subjects_affected="61" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Dermatitis, focal</sub_title>
                <description>associated with high-dose chemotherapy and bone marrow transplant</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <description>(e.g. Stevens-Johnson syndrome, toxic epidermal necrolysis)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" events="47" subjects_affected="37" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Nail discoloration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Nail loss</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Petechiae/purpura (hemorrhage/bleeding into skin or mucosa)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Skin-Other (dry skin)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hot flashes/flashes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Phlebitis (superficial)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Prothrombin time (PT)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tito Fojo, M.D.</name_or_title>
      <organization>National Cancer Institute, National Institutes of Health</organization>
      <phone>301-496-2631</phone>
      <email>FojoT@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

